论文部分内容阅读
目的观察艾普拉唑7 d三联疗法及10 d序贯疗法根除幽门螺杆菌(Hp)的临床疗效。方法 142例经电子胃镜、RUT检查证实Hp阳性的慢性胃炎患者,随机分成3组。A组予艾普拉唑5 mg+阿莫西林克拉维酸钾0.914 g+呋喃唑酮0.1g,bid,疗程7 d;B组予艾普拉唑5 mg+阿莫西林克拉维酸钾0.914 g,疗程5 d,继之艾普拉唑5 mg+克拉霉素0.5 g+呋喃唑酮0.1g,疗程5 d,共计10 d,每天均给药2次;C组予埃索美拉唑20 mg+阿莫西林克拉维酸钾0.914 g+呋喃唑酮0.1 g,bid,疗程7 d。疗程结束4周后行~(14)C-尿素呼气试验(~(14)C-UBT),观察Hp根除率、症状缓解率及不良反应发生情况。结果 A、B、C组患者症状缓解率比较差异无统计学意义(P>0.05);Hp根除率分别为60%、58.54%和55.26%,经检验P均>0.05。3组患者均无明显不良反应发生。结论 3组用药方案虽能达到良好的症状缓解率,但Hp根除率均未超过60%,低于理想标准。
Objective To observe the clinical efficacy of Ilaprazole 7 d triple therapy and 10 days sequential therapy in the eradication of Helicobacter pylori (Hp). Methods A total of 142 patients with Hp-positive chronic gastritis confirmed by electronic endoscopy and RUT were randomly divided into 3 groups. Group A was given ioprazole 5 mg + amoxicillin potassium clavulanate 0.914 g + furazolidone 0.1 g, bid for 7 days. Group B was given ilaprazole 5 mg + amoxicillin potassium clavulanate 0.914 g for 5 d , Followed by ilaprazole 5 mg + clarithromycin 0.5 g + furazolidone 0.1 g, course of treatment 5 d, a total of 10 d, administered twice a day; C group to esomeprazole 20 mg + amoxicillin potassium clavulanate 0.914 g furazolidone 0.1 g, bid, treatment 7 d. Four weeks after the end of treatment, the ~ (14) C-urea breath test (~ (14) C-UBT) was performed to observe the eradication rate of Hp, the rate of symptom relief and the incidence of adverse reactions. Results There was no significant difference in the remission rate between A, B and C groups (P> 0.05). The eradication rates of Hp were 60%, 58.54% and 55.26% respectively Adverse reactions occurred. Conclusion Although the three groups of drug regimens can achieve good symptom response rate, the Hp eradication rate did not exceed 60%, lower than the ideal standard.